Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations
Gidding SS, Wiegman A, Groselj U, Freiberger T, Peretti N, Dharmayat K, Daccord M, Bedlington N, Sikonja J, Ray KK, Santos RD, Halle M, Tokgozoglu L, Gutierrez-Ibarluzea I, Pinto FJ, Geanta M (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Book Volume: 29
Pages Range: 2301-2311
Journal Issue: 18
Abstract
Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe leading to significantly higher risk for premature heart disease in those affected. As treatment beginning early in life is highly effective in preventing heart disease and cost-effective in these patients, screening for FH is crucial. It has therefore now been recognized by the European Commission Public Health Best Practice Portal as an effective strategy. Model programmes exist in Europe to identify young individuals with FH, which are based on cascade screening of first-degree relatives of affected individuals, universal screening for high cholesterol, opportunistic screening of high-risk individuals, or a combination of the above approaches. Recommendations presented herein to improve identification of FH emphasize that every country should have an FH screening programme. These programmes should be adapted from existing strategies to best fit the individual country's healthcare system, governments should provide financial support for these programmes and related care, and further research to optimize care and implementations should be conducted.
Involved external institutions
FH Europe
United Kingdom (GB)
University of Amsterdam
Netherlands (NL)
Ljubljana University Medical Centre (Ljubljana UMC) / Univerzitetni klinični center Ljubljana
Slovenia (SI)
Center of Cardiovascular and Transplant Surgery / Centrum kardiovaskulární a transplantační chirurgie
Czech Republic (CZ)
Hospices Civils de Lyon (CHU)
France (FR)
Imperial College London / The Imperial College of Science, Technology and Medicine
United Kingdom (GB)
University of São Paulo / Universidade de São Paulo (USP)
Brazil (BR)
Technische Universität München (TUM)
Germany (DE)
Hacettepe University
Turkey (TR)
Basque Foundation for Health Innovation and Research (BIOEF)
Spain (ES)
World Heart Federation (WHF)
Switzerland (CH)
United Kingdom (GB)
University of Amsterdam
Netherlands (NL)
Ljubljana University Medical Centre (Ljubljana UMC) / Univerzitetni klinični center Ljubljana
Slovenia (SI)
Center of Cardiovascular and Transplant Surgery / Centrum kardiovaskulární a transplantační chirurgie
Czech Republic (CZ)
Hospices Civils de Lyon (CHU)
France (FR)
Imperial College London / The Imperial College of Science, Technology and Medicine
United Kingdom (GB)
University of São Paulo / Universidade de São Paulo (USP)
Brazil (BR)
Technische Universität München (TUM)
Germany (DE)
Hacettepe University
Turkey (TR)
Basque Foundation for Health Innovation and Research (BIOEF)
Spain (ES)
World Heart Federation (WHF)
Switzerland (CH)
How to cite
APA:
Gidding, S.S., Wiegman, A., Groselj, U., Freiberger, T., Peretti, N., Dharmayat, K.,... Geanta, M. (2022). Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. European Journal of Preventive Cardiology, 29(18), 2301-2311. https://doi.org/10.1093/eurjpc/zwac200
MLA:
Gidding, Samuel S., et al. "Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations." European Journal of Preventive Cardiology 29.18 (2022): 2301-2311.
BibTeX: Download